Nektar Therapeutics (FRA:ITH0) Moat Score: 3/10 (As of Jun. 30, 2026)


FRA:ITH0 Nektar Therapeutics FRA:ITH0
47 GF Score
Price €55.06
GF Value €5.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Moat Score?

Nektar Therapeutics FRA:ITH0 +2.69% 47 Moat Score is 3 as of Jun. 30, 2026. GuruFocus rates FRA:ITH0 with a GF Score™ of 47/100 and a GF Value™ of €5.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,401 Biotechnology companies, Nektar Therapeutics ranks better than 75.52% on this metric.

Nektar Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Nektar Therapeutics has No Moat: Nektar Therapeutics operates in the competitive biotech industry with limited market share and no significant intellectual property or regulatory barriers. The company's innovation efforts have not yet translated into a sustainable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Nektar Therapeutics might have No Moat - Very weak/transient advantages.

Nektar Therapeutics  (FRA:ITH0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Nektar Therapeutics Moat Score Related Terms

FRA:ITH0 vs OCUL, PVLA, GENB: Moat Score Comparison

For the Biotechnology subindustry, Nektar Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Moat Score falls into.


FRA:ITH0
47GF Score
Nektar Therapeutics FRA:ITH0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Nektar Therapeutics (FRA:ITH0) has a Moat Score of 3 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Nektar Therapeutics ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Nektar Therapeutics' Moat Score too high?
Nektar Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Nektar Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Nektar Therapeutics ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nektar Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Moat Score compare to OCUL and PVLA?
According to the Biotechnology industry distribution chart, Nektar Therapeutics ranks #343 out of 1401 companies for Moat Score. This places Nektar Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Nektar Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nektar Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nektar Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.05, compared to a current price of €55.06 — trading 990.3% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Moat Score is 3 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €55.06 is trading 990.3% above its estimated GF Value™ of €5.05. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Moat Score: 3
  • GF Value™: €5.05 vs. price of €55.06 (990.3% above fair value)
  • GF Score™: 47/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1401)

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for FRA:ITH0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.06
Price
€5.05
GF Value